Search - tctmd.com

Displaying 1 - 20 of 66

Sort: Relevancy | Date

ENCIRCLE: Good Results With Sapien M3 Transseptal TMVR

News Conference News TCT 2025

ENCIRCLE: Good Results With Sapien M3 Transseptal TMVR

October 27, 2025

Tendyne Safely Reduces MR in Patients With Severe Calcification: SUMMIT-MAC

News Conference News TCT 2025

Tendyne Safely Reduces MR in Patients With Severe Calcification: SUMMIT-MAC

Yael L. Maxwell

October 27, 2025

PREVUE-VALVE Charts the Prevalence of Valve Disease in the United States

News Conference News TCT 2025

PREVUE-VALVE Charts the Prevalence of Valve Disease in the United States

October 27, 2025

What’s Going to Be Hot at TCT 2025

News Opinion Editor's Corner TCT 2025

What’s Going to Be Hot at TCT 2025

Michael O'Riordan

October 09, 2025

Percutaneous Mechanical Aspiration Promising for Right-Heart Infective Endocarditis

News Conference News TCT 2024

Percutaneous Mechanical Aspiration Promising for Right-Heart Infective Endocarditis

November 08, 2024

ALIGN-AR at 2 Years Shows Promise for TAVI With Trilogy in Aortic Regurgitation

News Conference News TCT 2024

ALIGN-AR at 2 Years Shows Promise for TAVI With Trilogy in Aortic Regurgitation

Yael L. Maxwell

October 29, 2024

TTVR – is the Future! Lessons from Clinical Trials and Case Experiences

Presentation TCT 2024

TTVR – is the Future! Lessons from Clinical Trials and Case Experiences

Presenter: Azeem Latib

October 29, 2024

Overview of IASD Trials: Where Do We Stand?

Presentation TCT 2024

Overview of IASD Trials: Where Do We Stand?

Presenter: JoAnn Lindenfeld

October 28, 2024

Interatrial Shunts (IASD): From Theory to Clinical Trials

Presentation TCT 2024

Interatrial Shunts (IASD): From Theory to Clinical Trials

Presenter: Javed Butler

October 28, 2024

Protecting Coronary Access After TAVI: Valve Choice Clues From CAVEAT

News Conference News TCT 2024

Protecting Coronary Access After TAVI: Valve Choice Clues From CAVEAT

Michael O'Riordan

October 27, 2024

LAAO Outcomes Similar Regardless of Operator’s Specialty

News Conference News TCT 2024

LAAO Outcomes Similar Regardless of Operator’s Specialty

October 27, 2024

What’s Going to Be Big at TCT 2024?

News Opinion Editor's Corner TCT 2024

What’s Going to Be Big at TCT 2024?

Michael O'Riordan

October 17, 2024

VIVA: No Difference Between TAVI and SAVR for Small Aortic Annuli

News Conference News TCT 2023

VIVA: No Difference Between TAVI and SAVR for Small Aortic Annuli

October 27, 2023

‘Big Step Forward’ for Transcatheter Tricuspid Valve Replacement: TRISCEND II

News Conference News TCT 2023

‘Big Step Forward’ for Transcatheter Tricuspid Valve Replacement: TRISCEND II

Michael O'Riordan

October 26, 2023

CLASP IID at 1 Year: Good Results With Both Pascal, MitraClip for Mitral TEER

News Conference News TCT 2023

CLASP IID at 1 Year: Good Results With Both Pascal, MitraClip for Mitral TEER

October 26, 2023

The Future of Transcatheter Therapies for AR: The Impact of the ALIGN-AR Trial

Presentation TCT 2023

The Future of Transcatheter Therapies for AR: The Impact of the ALIGN-AR Trial

Presenter: Martin Leon

October 24, 2023

WATCH-TAVR: Adding LAAO to TAVI No Worse Than TAVI Alone

News Conference News TCT 2023

WATCH-TAVR: Adding LAAO to TAVI No Worse Than TAVI Alone

October 24, 2023

Ultrasound for Femoral Access? Neutral Results vs Common Sense: UNIVERSAL

News Conference News TCT 2022

Ultrasound for Femoral Access? Neutral Results vs Common Sense: UNIVERSAL

Yael L. Maxwell

September 19, 2022

Ongoing Clinical Trials and the Future of LAAC

Presentation TCT 2022

Ongoing Clinical Trials and the Future of LAAC

Presenter: Matthew Price

September 18, 2022

Expanding the Boundaries of MR Treatments with Early Results from the SUMMIT Trial

Presentation TCT 2022

Expanding the Boundaries of MR Treatments with Early Results from the SUMMIT Trial

Presenter: Gorav Ailawadi

September 17, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.